MSA
NBIX icon

Marino Stram & Associates’s Neurocrine Biosciences NBIX Stock Holding History

Marino Stram & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,052
Closed -$297K – 236
2021
Q2 		$297K Buy
+3,052
New +$293K 0.08% 208

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Marino Stram & Associates's NBIX Position: Q3 2021 in Review

Marino Stram & Associates sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 3,052 shares — an estimated $297K sold.

Marino Stram & Associates first reported a position in NBIX in Q2 2021 and held it in 1 quarter. The position peaked at $297K in Q2 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Marino Stram & Associates reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
  • Marino Stram & Associates sold 3,052 Neurocrine Biosciences shares in Q3 2021, an estimated $297K.
  • Marino Stram & Associates first reported a position in Neurocrine Biosciences in Q2 2021 and held it in 1 quarter.
  • Marino Stram & Associates's Neurocrine Biosciences position peaked at $297K in Q2 2021.
  • 395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Marino Stram & Associates's 13F filing for Q3 2021, filed 14 Oct 2021.